Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine

References

• Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 2005;437(7057):376–380.
   PubMed Web of Science ®Google Scholar
• Bakker E. Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessed. Clin Chem. 2006;52(4):557–558.
   PubMed Web of Science ®Google Scholar
• Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med. 2013;369(25):2369–2371.
   PubMed Web of Science ®Google Scholar
• Faruki H. Genomic testing: the clinical laboratory perspective. Clin Pharmacol Ther. 2013;94(2):190–192.
   PubMed Web of Science ®Google Scholar
• Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the future is here. Genet Med. 2013;15(4):258–267.
   PubMed Web of Science ®Google Scholar
• Meyer UA. Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5(9):669–676.
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529–537.
   PubMed Web of Science ®Google Scholar
• Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem. 1997;43(2):254–266.
   PubMed Web of Science ®Google Scholar
• Ji Y, Moon I, Zlatkovic J, et al. Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J Pharmacol Exp Ther. 2007;322(2):529–540.
   PubMed Web of Science ®Google Scholar
• Ji Y, Salavaggione OE, Wang L, et al. Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem. 2005;95(6):1766–1776.
   PubMed Web of Science ®Google Scholar
• Ji Y, Biernacka J, Snyder K, et al. Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J. 2012;12(1):78–85.
   PubMed Web of Science ®Google Scholar
• Ji Y, Biernacka JM, Hebbring S, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J. 2013;13(5):456–463.
   PubMed Web of Science ®Google Scholar
• Ji Y, Olson J, Zhang J, et al. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res. 2008;68(14):5997–6005.
   PubMed Web of Science ®Google Scholar
• Liu M, Goss PE, Ingle JN, et al. Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics. Mol Endocrinology. 2014;28(10):1740–1751.
   PubMed Web of Science ®Google Scholar
• Ji Y, Schaid DJ, Desta Z, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014;78(2):373–383.
   PubMed Web of Science ®Google Scholar
• Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–1153.
   PubMed Web of Science ®Google Scholar
• Hall FS, Drgonova J, Jain S, et al. Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther. 2013;140(3):267–279.
   PubMed Web of Science ®Google Scholar
• Clarke TK, Bloch PJ, Ambrose-Lanci LM, et al. Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis. Addict Biol. 2013;18(4):702–708.
   PubMed Web of Science ®Google Scholar
• Arnaout R, Buck TP, Roulette P, et al. Predicting the cost and pace of pharmacogenomic advances: an evidence-based study. Clin Chem. 2013;59(4):649–657.
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, Relling MV, Peterson JF, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013;94(2):207–210.
   PubMed Web of Science ®Google Scholar
• Bank PC, Swen JJ, Guchelaar HJ. A nationwide cross-sectional survey of pharmacy students on pharmacogenetic testing in The Netherlands. Pharmacogenomics. 2018;19(4):311–319.
   PubMed Web of Science ®Google Scholar
• Just KS, Steffens M, Swen JJ, et al. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). Eur J Clin Pharmacol. 2017;73(10):1247–1252.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464–467.
   PubMed Web of Science ®Google Scholar
• Pratt VM, Del Tredici AL, Hachad H, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology. J Mol Diagn. 2018;20(3):269-276.
   PubMed Web of Science ®Google Scholar
• Motsinger-Reif AA, Jorgenson E, Relling MV, et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013;23(8):383–394.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics. 2010;11(6):843–864.
   PubMed Web of Science ®Google Scholar
• Chidambaran V, Ngamprasertwong P, Vinks AA, et al. Pharmacogenetics and anesthetic drugs. Curr Clin Pharmacol. 2012;7(2):78–101.
   PubMedGoogle Scholar
• Hajj A, Khabbaz L, Laplanche JL, et al. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics. 2013;14(5):575–585.
   PubMed Web of Science ®Google Scholar
• Martin MA, Klein TE, Dong BJ, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734–738.
   PubMed Web of Science ®Google Scholar
• Martin MA, Hoffman JM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499–500.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673.
   PubMed Web of Science ®Google Scholar
• Foster RH, Faulds D. Abacavir. Drugs. 1998;55(5):729–736;discussion 737–728.
   Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727–732.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568–579.
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clinical Infect Dis. 2008;46(7):1111–1118.
   PubMed Web of Science ®Google Scholar
• Squassina A, Manchia M, Manolopoulos VG, et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics. 2010;11(8):1149–1167.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14(6):335–342.
   PubMedGoogle Scholar
• Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. Aids. 2008;22(15):2025–2033.
   PubMed Web of Science ®Google Scholar
• Hughes CA, Foisy MM, Dewhurst N, et al. Comment: abacavir hypersensitivity reaction: an update. The Annals of Pharmacotherapy. 2008;42(10):1519–1520; author reply 1520–1511.
   Web of Science ®Google Scholar
• O’Donnell PH, Bush A, Spitz J, et al. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther. 2012;92(4):446–449.
   PubMed Web of Science ®Google Scholar
• O’Donnell PH, Danahey K, Jacobs M, et al. Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago “1,200 Patients Project”. Am J Med Genet C Semin Med Genet. 2014;166C(1):68–75.
   Google Scholar
• Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014;166C(1):45–55.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423–431.
   PubMed Web of Science ®Google Scholar
• Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clinic Proc. 2014;89(1):25–33.
   PubMed Web of Science ®Google Scholar
• Caraballo PJ, Hodge LS, Bielinski SJ, et al. Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med. 2017;19(4):421–429.
   PubMed Web of Science ®Google Scholar
• Ji Y, Skierka JM, Blommel JH, et al. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn. 2016;18(3):438–445.
   PubMed Web of Science ®Google Scholar
• Wang B, Yang LP, Zhang XZ, et al. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573–643.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91(2):321–326.
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genome Medicine. 2010;2(9):66.
   PubMedGoogle Scholar
• Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–382.
   PubMed Web of Science ®Google Scholar
• Kimura S, Umeno M, Skoda RC, et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989;45(6):889–904.
   PubMed Web of Science ®Google Scholar
• Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90(24):11825–11829.
   PubMed Web of Science ®Google Scholar
• Black JL 3rd, Walker DL, O’Kane DJ, et al. Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab Dispos. 2012;40(1):111–119.
   PubMed Web of Science ®Google Scholar
• Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Review Psychiatry. 2013;25(5):534–553.
   PubMed Web of Science ®Google Scholar
• Lyon E, Gastier Foster J, Palomaki GE, et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet Med. 2012;14(12):990–1000.
   PubMed Web of Science ®Google Scholar
• Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics. 2014;15(8):1055–1058.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223.
   PubMed Web of Science ®Google Scholar
• Dean L. Codeine therapy and CYP2D6 genotype. In: Pratt V, McLeod H, Dean L, et al., editors, Medical Genetics Summaries [Internet]. Bethesda, MD: National Center for Biotechnology Information (US). 2017.
   Google Scholar
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6–13.
   PubMed Web of Science ®Google Scholar
• Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician. 2009;55(11):1077–1078.
   PubMed Web of Science ®Google Scholar
• Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009;85(1):31–35.
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368(9536):704.
   PubMed Web of Science ®Google Scholar
• Kramer WE, Walker DL, O’Kane DJ, et al. CYP2D6: novel genomic structures and alleles. Pharmacogenet Genomics. 2009;19(10):813–822.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007;81(3):328–345.
   PubMed Web of Science ®Google Scholar
• Ji Y, Hebbring S, Zhu H, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2011;89(1):97–104.
   PubMed Web of Science ®Google Scholar
• Abo R, Hebbring S, Ji Y, et al. Merging pharmacometabolomics with pharmacogenomics using ‘1000 Genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012;22(4):247–253.
   PubMed Web of Science ®Google Scholar
• Wadelius M, Alfirevic A. Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing. Genome Medicine. 2011;3(12):78.
   PubMedGoogle Scholar
• Ratain MJ, Nakamura Y, Cox NJ. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther. 2013;94(2):185–187.
   PubMed Web of Science ®Google Scholar
• Godman B, Finlayson AE, Cheema PK. Personalizing health care: feasibility and future implications. BMC Med. 2013;11:179.
   PubMed Web of Science ®Google Scholar
• Crews KR, Hicks JK, Pui CH, et al. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467–475.
   PubMed Web of Science ®Google Scholar
• Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther. 2014;95(3):269–280.
   PubMed Web of Science ®Google Scholar
• Veenstra DL, Piper M, Haddow JE, et al. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med. 2013;15(1):14–24.
   PubMed Web of Science ®Google Scholar
• Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenomics knowledge base. Methods Mol Biol. 2013;1015:311–320.
   PubMedGoogle Scholar
• Mamanova L, Coffey AJ, Scott CE, et al. Target-enrichment strategies for next-generation sequencing. Nat Methods. 2010;7(2):111–118.
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26(10):1135–1145.
   PubMed Web of Science ®Google Scholar
• Ajay SS, Parker SC, Abaan HO, et al. Accurate and comprehensive sequencing of personal genomes. Genome Res. 2011;21(9):1498–1505.
   PubMed Web of Science ®Google Scholar
• Genomes Project C, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061–1073.
   PubMed Web of Science ®Google Scholar
• Chen K, Wallis JW, McLellan MD, et al. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods. 2009;6(9):677–681.
   PubMed Web of Science ®Google Scholar
• Clark MJ, Chen R, Lam HY, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011;29(10):908–914.
   PubMed Web of Science ®Google Scholar
• Coonrod EM, Margraf RL, Voelkerding KV. Translating exome sequencing from research to clinical diagnostics. Clinical Chem Lab Med CCLM/FESCC. 2012;50(7):1161–1168.
   Web of Science ®Google Scholar
• Kadalayil L, Rafiq S, Rose-Zerilli MJ, et al. Exome sequence read depth methods for identifying copy number changes. Brief Bioinform. 2015;16(3):380–392.
   PubMed Web of Science ®Google Scholar
• Fromer M, Moran JL, Chambert K, et al. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet. 2012;91(4):597–607.
   PubMed Web of Science ®Google Scholar
• Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312(18):1880–1887.
   PubMed Web of Science ®Google Scholar
• Wang H, Nettleton D, Ying K. Copy number variation detection using next generation sequencing read counts. BMC Bioinf. 2014;15:109.
   PubMed Web of Science ®Google Scholar
• Belkadi A, Bolze A, Itan Y, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA. 2015;112(17):5473–5478.
   PubMed Web of Science ®Google Scholar
• Claes KB, De Leeneer K. Dealing with pseudogenes in molecular diagnostics in the next-generation sequencing era. Methods Mol Biol. 2014;1167:303–315.
   PubMedGoogle Scholar
• Cressman AM, Piquette-Miller M. Epigenetics: a new link toward understanding human disease and drug response. Clin Pharmacol Ther. 2012;92(6):669–673.
   PubMed Web of Science ®Google Scholar
• Erlich RL, Jia X, Anderson S, et al. Next-generation sequencing for HLA typing of class I loci. BMC Genomics. 2011;12:42.
   PubMed Web of Science ®Google Scholar
• Gabriel C, Furst D, Fae I, et al. HLA typing by next-generation sequencing - getting closer to reality. Tissue Antigens. 2014;83(2):65–75.
   PubMedGoogle Scholar
• Niklas N, Proll J, Danzer M, et al. Routine performance and errors of 454 HLA exon sequencing in diagnostics. BMC Bioinf. 2013;14:176.
   PubMed Web of Science ®Google Scholar
• Danzer M, Niklas N, Stabentheiner S, et al. Rapid, scalable and highly automated HLA genotyping using next-generation sequencing: a transition from research to diagnostics. BMC Genomics. 2013;14:221.
   PubMed Web of Science ®Google Scholar
• Ehrenberg PK, Geretz A, Baldwin KM, et al. High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual tagging. BMC Genomics. 2014;15:864.
   PubMed Web of Science ®Google Scholar
• Hosomichi K, Jinam TA, Mitsunaga S, et al. Phase-defined complete sequencing of the HLA genes by next-generation sequencing. BMC Genomics. 2013;14:355.
   PubMed Web of Science ®Google Scholar
• Jones B. Complex traits: predicting phenotypes. Nat Rev Genet. 2012;13(7):450.
   PubMed Web of Science ®Google Scholar
• Ober U, Ayroles JF, Stone EA, et al. Using whole-genome sequence data to predict quantitative trait phenotypes in Drosophila melanogaster. PLoS Genetics. 2012;8(5):e1002685.
   PubMed Web of Science ®Google Scholar
• Torkamani A, Scott-Van Zeeland AA, Topol EJ, et al. Annotating individual human genomes. Genomics. 2011;98(4):233–241.
   PubMed Web of Science ®Google Scholar
• Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med. 2013;369(16):1502–1511.
   PubMed Web of Science ®Google Scholar
• Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;312(18):1870–1879.
   PubMed Web of Science ®Google Scholar
• Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249–255.
   PubMed Web of Science ®Google Scholar